Evaluation of the Efficacy and Safety of Bumetanide in Parkinson's Disease
Status:
Unknown status
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This is multicentre, proof of concept, randomized, double-blind, parallel-group,
placebo-control study in 40 Parkinson's Disease (PD) patients. Patients will be randomized in
2 groups receiving Bumetanide or placebo for 4 months:
- Group 1 (20 PD patients): bumetanide
- Group 2 (20 PD patients): placebo intake identically to group 1.